RT Journal Article
SR Electronic
T1 WITHDRAWN: A gene expression-based diagnostic classifier for identification of severe COVID-19 and multisystem inflammatory syndrome in children (MIS-C)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.26.22280395
DO 10.1101/2022.09.26.22280395
A1 Sotomayor-Gonzalez, Alicia
A1 Loy, Conor J.
A1 Nguyen, Jenny
A1 Servellita, Venice
A1 Bhattacharya, Sanchita
A1 Lenz, Joan
A1 Williams, Meagan
A1 Suslovic, Will
A1 Cheng, Alexandre P.
A1 Bliss, Andrew
A1 Saldhi, Prachi
A1 Streithorst, Jessica
A1 Huh, Hee Jae
A1 Foresythe, Abiodun
A1 Oseguera, Miriam
A1 de la Cruz, Katrina
A1 Brazer, Noah
A1 Wood, Nathan
A1 Hsieh, Charlotte
A1 Bahar, Burak
A1 Gliwa, Amelia
A1 Bhakta, Kushmita
A1 Perez, Maria A.
A1 Anderson, Evan J.
A1 Chahroudi, Ann
A1 Delaney, Meghan
A1 Butte, Atul J.
A1 DeBiasi, Roberta
A1 Rostad, Christina A.
A1 De Vlaminck, Iwijn
A1 Chiu, Charles
YR 2023
UL http://medrxiv.org/content/early/2023/12/05/2022.09.26.22280395.abstract
AB The authors have withdrawn their manuscript owing to data from patients who had not been consented being inadvertently used in the preprint. This has been corrected in the version of the study published in Cell Reports Medicine. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.Competing Interest StatementI.D.V. is a member of the Scientific Advisory Board of Karius Inc., Kanvas Biosciences and GenDX. C.Y.C. is a founder and a member of the Scientific Advisory Board of Delve Bio. I.D.V. and A.P.C. are listed as an inventor on submitted patents pertaining to cell-free DNA (US patent applications 63/237,367, 63/056,249, 63/015,095, 16/500,929) and receive consulting fees from Eurofins Viracor. C.A.R. received funding to conduct clinical research unrelated to this manuscript from BioFire Inc., GSK, MedImmune, Micron, Merck, Novavax, PaxVax, Regeneron, Pfizer, and Sanofi-Pasteur. She is co-inventor of patented RSV vaccine technology (International PCT Application No. PCT/US2016/058976, filed 12/28/2016 by Emory University), which has been licensed to Meissa Vaccines, Inc. with royalties received. Her institution has received funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. E.J.A has consulted for Pfizer, Sanofi Pasteur, GSK, Janssen, and Medscape, and his institution receives funds to conduct clinical research unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Sanofi-Pasteur, Janssen, and Micron. He also serves on a safety monitoring board for Kentucky BioProcessing, Inc. and Sanofi Pasteur. He serves on a data adjudication board for WCG and ACI Clinical. His institution has also received funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. A.B. is a co-founder and consultant to Personalis and NuMedii; consultant to Mango Tree Corporation, and in the recent past, Samsung, 10x Genomics, Helix, Pathway Genomics, and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, and Merck, and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Meta (Facebook), Alphabet (Google), Microsoft, Amazon, Snap, 10x Genomics, Illumina, Regeneron, Sanofi, Pfizer, Royalty Pharma, Moderna, Sutro, Doximity, BioNtech, Invitae, Pacific Biosciences, Editas Medicine, Nuna Health, Assay Depot, and Vet24seven, and several other non-health related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Johnson and Johnson, Roche, Genentech, Pfizer, Merck, Lilly, Takeda, Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Westat, and many academic institutions, medical or disease specific foundations and associations, and health systems. A.B. receives royalty payments through Stanford University, for several patents and other disclosures licensed to NuMedii and Personalis. Research from A.B. has been funded by NIH, Peraton (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor Office of Planning and Research, California Institute for Regenerative Medicine, LOreal, and Progenity. The authors have declared that none of these companies or competing interests had any role in this work or manuscript.Funding StatementThis work was supported by the National Institutes of Health (NIH) / National Institute of Child Health and Human Development (NICHD) grant R61HD105618 (R.D., C.A.R., I.D.V., and C.Y.C.). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of California, San Francisco (UCSF) Institutional Review Board (IRB) (#21-33403), San Francisco, CA; Emory University IRB (STUDY00000723), Atlanta, GA; Childrens National Medical Center (CNMC) IRB (Pro00010632), Washington, DC; and Cornell University IRB for Human Participants (2012010003), New York, NY each approved the protocols for this study. All samples and patient information were de-identified for analysis and sharing with collaboration institutions. At Emory University the IRB approved protocol was a prospective enrollment study under which parents provided consent and children assent as appropriate for age. At CNMC and UCSF, the IRB protocols were no subject contact sample biobanking protocols under which content was not obtained and data was extracted from medical charts.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes